PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world’s leading surgical conferences PETACH TIKVA, Israel , Sept. 30, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to